It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果